"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Bengt Rasmussen; Gudrun Göhring; Elsa Bernard; Lars Nilsson; Magnus Tobiasson; Martin Jädersten; Hege Garelius; Ingunn Dybedal; Kirsten Grønbaek; Elisabeth Ejerblad; Fryderyk Lorenz; Max Flogegård; Claus Werenberg Marcher; Annette Öster Fernström; Lucia Cavelier; Elli Papaemmanuil; Freja Ebeling; Astrid Olsnes Kittang; Jan Maxwell Nørgaard; Leonie Saft; Lars Möllgård; Eva Hellström-Lindberg

doi:10.1038/s41375-022-01537-w

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Bengt Rasmussen, Gudrun Göhring, Elsa Bernard, Lars Nilsson, Magnus Tobiasson, Martin Jädersten, Hege Garelius, Ingunn Dybedal, Kirsten Grønbaek, Elisabeth Ejerblad, Fryderyk Lorenz, Max Flogegård, Claus Werenberg Marcher, Annette Öster Fernström, Lucia Cavelier, Elli Papaemmanuil, Freja Ebeling, Astrid Olsnes Kittang, Jan Maxwell Nørgaard, Leonie SaftLars Möllgård, Eva Hellström-Lindberg

Department of Haematology

Original language	English
Journal	Leukemia
Volume	36
Issue number	5
Pages (from-to)	1436-1439
Number of pages	4
ISSN	0887-6924
DOIs	https://doi.org/10.1038/s41375-022-01537-w
Publication status	Published - May 2022

Keywords

Azacitidine
Chromosome Deletion
Chromosomes, Human, Pair 5/genetics
Humans
Karyotype
Lenalidomide/therapeutic use
Leukemia, Myeloid, Acute/drug therapy
Myelodysplastic Syndromes/drug therapy

Access to Document

10.1038/s41375-022-01537-w

Cite this

Rasmussen, B., Göhring, G., Bernard, E., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H., Dybedal, I., Grønbaek, K., Ejerblad, E., Lorenz, F., Flogegård, M., Marcher, C. W., Öster Fernström, A., Cavelier, L., Papaemmanuil, E., Ebeling, F., Kittang, A. O., Nørgaard, J. M., ... Hellström-Lindberg, E. (2022). "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)". Leukemia, 36(5), 1436-1439. https://doi.org/10.1038/s41375-022-01537-w

Rasmussen, B, Göhring, G, Bernard, E, Nilsson, L, Tobiasson, M, Jädersten, M, Garelius, H, Dybedal, I, Grønbaek, K, Ejerblad, E, Lorenz, F, Flogegård, M, Marcher, CW, Öster Fernström, A, Cavelier, L, Papaemmanuil, E, Ebeling, F, Kittang, AO, Nørgaard, JM, Saft, L, Möllgård, L & Hellström-Lindberg, E 2022, '"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"', Leukemia, vol. 36, no. 5, pp. 1436-1439. https://doi.org/10.1038/s41375-022-01537-w

@article{4a77bca6b71f4f47944b43b4b8e2d270,

title = "{"}Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q){"}",

keywords = "Azacitidine, Chromosome Deletion, Chromosomes, Human, Pair 5/genetics, Humans, Karyotype, Lenalidomide/therapeutic use, Leukemia, Myeloid, Acute/drug therapy, Myelodysplastic Syndromes/drug therapy",

author = "Bengt Rasmussen and Gudrun G{\"o}hring and Elsa Bernard and Lars Nilsson and Magnus Tobiasson and Martin J{\"a}dersten and Hege Garelius and Ingunn Dybedal and Kirsten Gr{\o}nbaek and Elisabeth Ejerblad and Fryderyk Lorenz and Max Flogeg{\aa}rd and Marcher, {Claus Werenberg} and {{\"O}ster Fernstr{\"o}m}, Annette and Lucia Cavelier and Elli Papaemmanuil and Freja Ebeling and Kittang, {Astrid Olsnes} and N{\o}rgaard, {Jan Maxwell} and Leonie Saft and Lars M{\"o}llg{\aa}rd and Eva Hellstr{\"o}m-Lindberg",

year = "2022",

month = may,

doi = "10.1038/s41375-022-01537-w",

language = "English",

volume = "36",

pages = "1436--1439",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

AU - Rasmussen, Bengt

AU - Göhring, Gudrun

AU - Bernard, Elsa

AU - Nilsson, Lars

AU - Tobiasson, Magnus

AU - Jädersten, Martin

AU - Garelius, Hege

AU - Dybedal, Ingunn

AU - Grønbaek, Kirsten

AU - Ejerblad, Elisabeth

AU - Lorenz, Fryderyk

AU - Flogegård, Max

AU - Marcher, Claus Werenberg

AU - Öster Fernström, Annette

AU - Cavelier, Lucia

AU - Papaemmanuil, Elli

AU - Ebeling, Freja

AU - Kittang, Astrid Olsnes

AU - Nørgaard, Jan Maxwell

AU - Saft, Leonie

AU - Möllgård, Lars

AU - Hellström-Lindberg, Eva

PY - 2022/5

Y1 - 2022/5

KW - Azacitidine

KW - Chromosome Deletion

KW - Chromosomes, Human, Pair 5/genetics

KW - Humans

KW - Karyotype

KW - Lenalidomide/therapeutic use

KW - Leukemia, Myeloid, Acute/drug therapy

KW - Myelodysplastic Syndromes/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85126099436&partnerID=8YFLogxK

U2 - 10.1038/s41375-022-01537-w

DO - 10.1038/s41375-022-01537-w

M3 - Letter

C2 - 35277655

SN - 0887-6924

VL - 36

SP - 1436

EP - 1439

JO - Leukemia

JF - Leukemia

IS - 5

ER -

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"

Keywords

Access to Document

Other files and links

Cite this